Sequence-dependent cross-resistance of combined radiotherapy plus BRAF V600E inhibition in melanoma
Introduction - Treatment of patients with metastatic melanoma is hampered by drug-resistance and often requires combination with radiotherapy as last-resort option. However, also after radiotherapy, clinical relapses are common. - Methods & results - Our preclinical models indicated a higher rat...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | |
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2 February 2019
|
| In: |
European journal of cancer
Year: 2019, Jahrgang: 109, Pages: 137-153 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2018.12.024 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ejca.2018.12.024 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804919300012 
|
| Verfasserangaben: | B. Shannan, J. Matschke, H. Chauvistré, F. Vogel, D. Klein, F. Meier, D. Westphal, J. Bruns, R. Rauschenberg, J. Utikal, A. Forschner, C. Berking, P. Terheyden, E. Dabrowski, R. Gutzmer, D. Rafei-Shamsabadi, F. Meiss, L. Heinzerling, L. Zimmer, Elisabeth Livingstone, Renáta Váraljai, A. Hoewner, S. Horn, J. Klode, M. Stuschke, B. Scheffler, A. Marchetto, G. Sannino, T.G.P. Grünewald, D. Schadendorf, V. Jendrossek, A. Roesch |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1675738521 | ||
| 003 | DE-627 | ||
| 005 | 20240323101255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190903s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2018.12.024 |2 doi | |
| 035 | |a (DE-627)1675738521 | ||
| 035 | |a (DE-599)KXP1675738521 | ||
| 035 | |a (OCoLC)1341242470 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Shannan, Batool |d 1982- |e VerfasserIn |0 (DE-588)132922592 |0 (DE-627)528679228 |0 (DE-576)263048659 |4 aut | |
| 245 | 1 | 0 | |a Sequence-dependent cross-resistance of combined radiotherapy plus BRAF V600E inhibition in melanoma |c B. Shannan, J. Matschke, H. Chauvistré, F. Vogel, D. Klein, F. Meier, D. Westphal, J. Bruns, R. Rauschenberg, J. Utikal, A. Forschner, C. Berking, P. Terheyden, E. Dabrowski, R. Gutzmer, D. Rafei-Shamsabadi, F. Meiss, L. Heinzerling, L. Zimmer, Elisabeth Livingstone, Renáta Váraljai, A. Hoewner, S. Horn, J. Klode, M. Stuschke, B. Scheffler, A. Marchetto, G. Sannino, T.G.P. Grünewald, D. Schadendorf, V. Jendrossek, A. Roesch |
| 246 | 3 | 0 | |a V600 E |
| 264 | 1 | |c 2 February 2019 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel ist V600E hochgestellt | ||
| 500 | |a Gesehen am 10.09.2019 | ||
| 520 | |a Introduction - Treatment of patients with metastatic melanoma is hampered by drug-resistance and often requires combination with radiotherapy as last-resort option. However, also after radiotherapy, clinical relapses are common. - Methods & results - Our preclinical models indicated a higher rate of tumour relapse when melanoma cells were first treated with BRAFV600E inhibition (BRAFi) followed by radiotherapy as compared to the reverse sequence. Accordingly, retrospective follow-up data from 65 stage-IV melanoma patients with irradiated melanoma brain metastases confirmed a shortened duration of local response of mitogen-activated protein kinase (MAPK)-inhibitor-pretreated compared with MAPK-inhibitor-naïve intracranial metastases. On the molecular level, we identified JARID1B/KDM5B as a cellular marker for cross-resistance between BRAFi and radiotherapy. JARID1Bhigh cells appeared more frequently under upfront BRAFi as compared with upfront radiation. JARID1B favours cell survival by transcriptional regulation of genes controlling cell cycle, DNA repair and cell death. - Conclusion - The level of cross-resistance between combined MAPK inhibition and radiotherapy is dependent on the treatment sequence. JARID1B may represent a novel therapy-overarching resistance marker. | ||
| 650 | 4 | |a Cross-resistance | |
| 650 | 4 | |a JARID1B/KDM5B | |
| 650 | 4 | |a Melanoma | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Repopulation | |
| 650 | 4 | |a Resistance | |
| 650 | 4 | |a Slow-cycling cells | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 4 | |a Therapy sequencing | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 109(2019), Seite 137-153 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Sequence-dependent cross-resistance of combined radiotherapy plus BRAF V600E inhibition in melanoma |
| 773 | 1 | 8 | |g volume:109 |g year:2019 |g pages:137-153 |g extent:17 |a Sequence-dependent cross-resistance of combined radiotherapy plus BRAF V600E inhibition in melanoma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2018.12.024 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804919300012 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190903 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 23 | ||
| 999 | |a KXP-PPN1675738521 |e 3511296323 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"disp":"Sequence-dependent cross-resistance of combined radiotherapy plus BRAF V600E inhibition in melanomaEuropean journal of cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["28.1992 -"],"part":{"year":"2019","extent":"17","volume":"109","text":"109(2019), Seite 137-153","pages":"137-153"},"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"European Organization for Research on Treatment of Cancer"},{"display":"European Association for Cancer Research","role":"isb","roleDisplay":"Herausgebendes Organ"},{"display":"European School of Oncology","role":"isb","roleDisplay":"Herausgebendes Organ"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"language":["eng"],"id":{"eki":["266883400"],"issn":["1879-0852"],"zdb":["1468190-0"]},"recId":"266883400","titleAlt":[{"title":"EJC online"}],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"Batool","role":"aut","roleDisplay":"VerfasserIn","display":"Shannan, Batool","family":"Shannan"},{"given":"Jochen","role":"oth","display":"Utikal, Jochen","family":"Utikal"}],"note":["Im Titel ist V600E hochgestellt","Gesehen am 10.09.2019"],"title":[{"title":"Sequence-dependent cross-resistance of combined radiotherapy plus BRAF V600E inhibition in melanoma","title_sort":"Sequence-dependent cross-resistance of combined radiotherapy plus BRAF V600E inhibition in melanoma"}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2 February 2019"}],"name":{"displayForm":["B. Shannan, J. Matschke, H. Chauvistré, F. Vogel, D. Klein, F. Meier, D. Westphal, J. Bruns, R. Rauschenberg, J. Utikal, A. Forschner, C. Berking, P. Terheyden, E. Dabrowski, R. Gutzmer, D. Rafei-Shamsabadi, F. Meiss, L. Heinzerling, L. Zimmer, Elisabeth Livingstone, Renáta Váraljai, A. Hoewner, S. Horn, J. Klode, M. Stuschke, B. Scheffler, A. Marchetto, G. Sannino, T.G.P. Grünewald, D. Schadendorf, V. Jendrossek, A. Roesch"]},"recId":"1675738521","id":{"eki":["1675738521"],"doi":["10.1016/j.ejca.2018.12.024"]},"physDesc":[{"extent":"17 S."}],"language":["eng"]} | ||
| SRT | |a SHANNANBATSEQUENCEDE2201 | ||